AIMS: To describe the effects of tolvaptan therapy on dyspnoea relief based on timing of delivery, influence of concomitant therapies, and baseline patient and clinical characteristics. Also, the influence of clinical trial design on dyspnoea measurement, from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trials. METHODS AND RESULTS: Post hoc analysis was performed based on the endpoint of patient-assessed dyspnoea. Changes from baseline at inpatient Day 1 were compared between treatment groups by the van Elteren test. Pre-determined subgroup analyses were also performed. Tolvaptan's effects are greatest within 12 h after first dose with an additional, but modest dyspnoea improvement benefit irrespective of time after admission. Overall, patients continue to report dyspnoea improvement up to 60 h after admission. The window of enrolment, up to 48 h after admission, combined with measurement on 'Day 1' led to a wide range over when dyspnoea was assessed. CONCLUSION: Post hoc analysis suggests that tolvaptan modestly improves dyspnoea compared with standard therapy alone, regardless if given early or relatively late after hospitalization, and also across major pre-specified subgroups, despite ongoing background therapy aimed at relieving signs and symptoms. Significant variability around when dyspnoea was assessed, in addition to the persistence of dyspnoea despite ongoing background therapy, may influence how future clinical trials assess dyspnoea in acute heart failure syndromes.
RCT Entities:
AIMS: To describe the effects of tolvaptan therapy on dyspnoea relief based on timing of delivery, influence of concomitant therapies, and baseline patient and clinical characteristics. Also, the influence of clinical trial design on dyspnoea measurement, from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trials. METHODS AND RESULTS: Post hoc analysis was performed based on the endpoint of patient-assessed dyspnoea. Changes from baseline at inpatient Day 1 were compared between treatment groups by the van Elteren test. Pre-determined subgroup analyses were also performed. Tolvaptan's effects are greatest within 12 h after first dose with an additional, but modest dyspnoea improvement benefit irrespective of time after admission. Overall, patients continue to report dyspnoea improvement up to 60 h after admission. The window of enrolment, up to 48 h after admission, combined with measurement on 'Day 1' led to a wide range over when dyspnoea was assessed. CONCLUSION: Post hoc analysis suggests that tolvaptan modestly improves dyspnoea compared with standard therapy alone, regardless if given early or relatively late after hospitalization, and also across major pre-specified subgroups, despite ongoing background therapy aimed at relieving signs and symptoms. Significant variability around when dyspnoea was assessed, in addition to the persistence of dyspnoea despite ongoing background therapy, may influence how future clinical trials assess dyspnoea in acute heart failure syndromes.
Authors: Mihai Gheorghiade; Wendy A Gattis; Alejandro Barbagelata; Kirkwood F Adams; Uri Elkayam; Cesare Orlandi; Christopher M O'Connor Journal: Am Heart J Date: 2003-02 Impact factor: 4.749
Authors: Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton Journal: Am Heart J Date: 2005-02 Impact factor: 4.749
Authors: Marvin A Konstam; Mihai Gheorghiade; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi Journal: JAMA Date: 2007-03-25 Impact factor: 56.272
Authors: Mihai Gheorghiade; Marvin A Konstam; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi Journal: JAMA Date: 2007-03-25 Impact factor: 56.272
Authors: Robert J Mentz; Keld Kjeldsen; Gian Paolo Rossi; Adriaan A Voors; John G F Cleland; Stefan D Anker; Mihai Gheorghiade; Mona Fiuzat; Patrick Rossignol; Faiez Zannad; Bertram Pitt; Christopher O'Connor; G Michael Felker Journal: Eur J Heart Fail Date: 2014-03-05 Impact factor: 15.534
Authors: David E Lanfear; Hani N Sabbah; Steven R Goldsmith; Stephen J Greene; Andrew P Ambrosy; Angela J Fought; Mary J Kwasny; Karl Swedberg; Clyde W Yancy; Marvin A Konstam; Aldo P Maggioni; Faiez Zannad; Mihai Gheorghiade Journal: Circ Heart Fail Date: 2012-12-12 Impact factor: 8.790
Authors: Robb D Kociol; Steven E McNulty; Adrian F Hernandez; Kerry L Lee; Margaret M Redfield; Russell P Tracy; Eugene Braunwald; Christopher M O'Connor; G Michael Felker Journal: Circ Heart Fail Date: 2012-12-18 Impact factor: 8.790
Authors: Marco Metra; John R Teerlink; G Michael Felker; Barry H Greenberg; Gerasimos Filippatos; Piotr Ponikowski; Sam L Teichman; Elaine Unemori; Adriaan A Voors; Beth Davison Weatherley; Gad Cotter Journal: Eur J Heart Fail Date: 2010-08-22 Impact factor: 15.534
Authors: Peter S Pang; Sean P Collins; Kori Sauser; Adin-Cristian Andrei; Alan B Storrow; Judd E Hollander; Miguel Tavares; Jindrich Spinar; Cezar Macarie; Dimitar Raev; Richard Nowak; Mihai Gheorghiade; Alexandre Mebazaa Journal: Acad Emerg Med Date: 2014-06 Impact factor: 3.451